6 results on '"Baddoo, Melody"'
Search Results
2. Viral reprogramming of host transcription initiation
- Author
-
Ungerleider, Nathan A, primary, Roberts, Claire, additional, O’Grady, Tina M, additional, Nguyen, Trang T, additional, Baddoo, Melody, additional, Wang, Jia, additional, Ishaq, Eman, additional, Concha, Monica, additional, Lam, Meggie, additional, Bass, Jordan, additional, Nguyen, Truong D, additional, Van Otterloo, Nick, additional, Wickramarachchige-Dona, Nadeeshika, additional, Wyczechowska, Dorota, additional, Morales, Maria, additional, Ma, Tianfang, additional, Dong, Yan, additional, and Flemington, Erik K, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Transcriptomic analysis identifies B-lymphocyte kinase as a therapeutic target for desmoplastic small round cell tumor cancer stem cell-like cells
- Author
-
Magrath, Justin W., primary, Flinchum, Dane A., additional, Hartono, Alifiani B., additional, Sampath, Shruthi Sanjitha, additional, O’Grady, Tina M., additional, Baddoo, Melody, additional, Haoyang, Liang, additional, Xu, Xiaojiang, additional, Flemington, Erik K., additional, and Lee, Sean B., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
- Author
-
Ma, Tianfang, Jin, Lianjin, Bai, Shanshan, Liu, Zhan, Wang, Shuo, Shen, Beibei, Cho, Yeyoung, Cao, Subing, Sun, Meijuan J S, Fazli, Ladan, Zhang, David, Wedderburn, Chiyaro, Zhang, Derek Y, Mugon, Gavisha, Ungerleider, Nathan, Baddoo, Melody, Zhang, Kun, Schiavone, Lovisa Holmberg, Burkhardt, Brant R, and Fan, Jia
- Subjects
ANDROGEN receptors ,PROSTATE cancer ,CANCER invasiveness ,GENETIC models ,GENE expression ,CHROMOSOMAL rearrangement ,GENE enhancers - Abstract
Background Although the fusion of the transmembrane serine protease 2 gene (TMPRSS2) with the erythroblast transformation-specific-related gene (ERG), or TMPRSS2-ERG, occurs frequently in prostate cancer, its impact on clinical outcomes remains controversial. Roughly half of TMPRSS2-ERG fusions occur through intrachromosomal deletion of interstitial genes and the remainder via insertional chromosomal rearrangements. Because prostate cancers with deletion-derived TMPRSS2-ERG fusions are more aggressive than those with insertional fusions, we investigated the impact of interstitial gene loss on prostate cancer progression. Methods We conducted an unbiased analysis of transcriptome data from large collections of prostate cancer samples and employed diverse in vitro and in vivo models combined with genetic approaches to characterize the interstitial gene loss that imposes the most important impact on clinical outcome. Results This analysis identified FAM3B as the top-ranked interstitial gene whose loss is associated with a poor prognosis. The association between FAM3B loss and poor clinical outcome extended to fusion-negative prostate cancers where FAM3B downregulation occurred through epigenetic imprinting. Importantly, FAM3B loss drives disease progression in prostate cancer. FAM3B acts as an intermediator of a self-governing androgen receptor feedback loop. Specifically, androgen receptor upregulates FAM3B expression by binding to an intronic enhancer to induce an enhancer RNA and facilitate enhancer-promoter looping. FAM3B, in turn, attenuates androgen receptor signaling. Conclusion Loss of FAM3B in prostate cancer, whether through the TMPRSS2-ERG translocation or epigenetic imprinting, causes an exit from this autoregulatory loop to unleash androgen receptor activity and prostate cancer progression. These findings establish FAM3B loss as a new driver of prostate cancer progression and support the utility of FAM3B loss as a biomarker to better define aggressive prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Obesity facilitated colon cancer progression is mediated by increased diacylglycerol o-acyltransferases 1 and 2 (DGAT1/2) levels.
- Author
-
Ghimire J, Collins ME, Snarski P, King AN, Ruiz E, Iftikhar R, Penrose HM, Moroz K, Rorison T, Baddoo M, Naeem MA, Zea AH, Magness ST, Flemington EF, Crawford SE, and Savkovic SD
- Abstract
Background & Aims: The obesity epidemic is associated with increased colon cancer progression. As lipid droplets (LDs) fuel tumor growth, we aim to determine the significance of diacyltransferases, DGAT1/2, responsible for LDs biogenesis, in obesity-mediated colonic tumorigenesis., Methods: Human colon cancer samples, colon cancer cells, colonospheres, and Apc
Min/+ colon cancer mouse model on a high-fat diet were employed. For DGAT1/2 inhibition, enzymatic inhibitors and siRNA were used. Expression, pathways, cell cycle, and growth were assessed. Bioinformatic analyses of CUT&RUN and RNAseq data were performed., Results: DGAT1/2 levels in human colon cancer tissue are significantly elevated with disease severity and obesity (vs normal). Their levels are increased in human colon cancer cells (vs non-transformed) and further enhanced by fatty acids prevalent in obesity; augmented DGAT2 expression is MYC-dependent. Inhibition of DGAT1/2 improves FOXO3 activity by attenuating PI3K, resulting in reduced MYC-dependent DGAT2 expression and LDs accumulation, suggesting feedback. This inhibition attenuated growth in colon cancer cells and colonospheres via FOXO3/p27kip1 cell cycle arrest and reduced colonic tumors in ApcMin/+ mice on a high-fat diet. Transcriptomic analysis revealed that DGAT1/2 inhibition targeted metabolic and tumorigenic pathways in human colon cancer and colon cancer crypts, stratifying human colon cancer samples from normal. Further analysis revealed that this inhibition is predictive of advanced disease-free state and survival in colon cancer patients., Conclusion: This is a novel mechanism of DGAT1/2-dependent metabolic and tumorigenic remodeling in obesity-facilitated colon cancer, providing a platform for the future development of effective treatments for colon cancer patients., (Copyright © 2024 AGA Institute. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
6. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
- Author
-
Ma T, Jin L, Bai S, Liu Z, Wang S, Shen B, Cho Y, Cao S, Sun MJS, Fazli L, Zhang D, Wedderburn C, Zhang DY, Mugon G, Ungerleider N, Baddoo M, Zhang K, Schiavone LH, Burkhardt BR, Fan J, You Z, Flemington EK, Dong X, and Dong Y
- Subjects
- Male, Humans, Feedback, Transcriptome, Oncogene Proteins, Fusion genetics, Transcriptional Regulator ERG genetics, Transcriptional Regulator ERG metabolism, Neoplasm Proteins genetics, Cytokines genetics, Receptors, Androgen genetics, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism
- Abstract
Background: Although the fusion of the transmembrane serine protease 2 gene (TMPRSS2) with the erythroblast transformation-specific-related gene (ERG), or TMPRSS2-ERG, occurs frequently in prostate cancer, its impact on clinical outcomes remains controversial. Roughly half of TMPRSS2-ERG fusions occur through intrachromosomal deletion of interstitial genes and the remainder via insertional chromosomal rearrangements. Because prostate cancers with deletion-derived TMPRSS2-ERG fusions are more aggressive than those with insertional fusions, we investigated the impact of interstitial gene loss on prostate cancer progression., Methods: We conducted an unbiased analysis of transcriptome data from large collections of prostate cancer samples and employed diverse in vitro and in vivo models combined with genetic approaches to characterize the interstitial gene loss that imposes the most important impact on clinical outcome., Results: This analysis identified FAM3B as the top-ranked interstitial gene whose loss is associated with a poor prognosis. The association between FAM3B loss and poor clinical outcome extended to fusion-negative prostate cancers where FAM3B downregulation occurred through epigenetic imprinting. Importantly, FAM3B loss drives disease progression in prostate cancer. FAM3B acts as an intermediator of a self-governing androgen receptor feedback loop. Specifically, androgen receptor upregulates FAM3B expression by binding to an intronic enhancer to induce an enhancer RNA and facilitate enhancer-promoter looping. FAM3B, in turn, attenuates androgen receptor signaling., Conclusion: Loss of FAM3B in prostate cancer, whether through the TMPRSS2-ERG translocation or epigenetic imprinting, causes an exit from this autoregulatory loop to unleash androgen receptor activity and prostate cancer progression. These findings establish FAM3B loss as a new driver of prostate cancer progression and support the utility of FAM3B loss as a biomarker to better define aggressive prostate cancer., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.